Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
This grant funds the validation of molecular, cellular, and imaging biomarkers and assays for cancer detection, diagnosis, prognosis, treatment response, and prevention, supporting both analytical and clinical validation phases.
Funder: National Institutes of Health
Due Dates: February 8, 2027 (Estimated, forecasted)
Funding Amounts: UH2/UH3 up to 5 years; standalone UH3 up to 3 years; award ceiling not specified
Summary: Supports validation of molecular, cellular, and imaging biomarkers and assays for cancer detection, diagnosis, prognosis, and treatment decision-making.
Key Information: This is a forecasted opportunity; details may change—check program page for updates.
Description
This funding opportunity from the National Cancer Institute (NCI), part of the NIH, is designed to support the validation of molecular, cellular, and imaging markers ("biomarkers") and assays for use in cancer clinical studies. It aims to advance assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as for cancer prevention and control. Applicants can propose either a biphasic UH2/UH3 (up to 5 years) or a standalone UH3 (up to 3 years) cooperative agreement. The UH2 phase supports analytical validation of assays, while the UH3 phase supports clinical validation using well-annotated biospecimens from retrospective or prospective studies. The opportunity also welcomes projects validating pharmacodynamic markers and markers of toxicity, and encourages multidisciplinary collaborations.
